胃癌血清的表面增强拉曼光谱研究

表面增强拉曼光谱技术在癌症诊断领域已经有了广泛的研究和应用,本文利用金纳米溶胶为增强基底,采用便携式近红外拉曼光谱系统,对89例胃癌患者及正常人血清样本进行了SERS光谱探测。结果表明,血清的特征峰主要归属于氨基酸,其次是核酸、糖类及脂类。相比于正常人血清SERS光谱,胃癌血清中归属于核酸的特征峰强度都较高,大部分归属于蛋白质的特征峰强度较低,与医学研究结论相符。说明SERS技术可以有效地反映胃癌患者和正常人血清的差异,为后期SERS技术快速诊断胃癌提供了实验基础。     

胃癌患者手术前后血清的激光拉曼光谱研究

为了探讨胃癌患者血清光谱在手术前后的变化及临床应用价值,用光谱法分别检测了30例胃癌细胞培养液、20例健康人血清和41例胃癌患者手术前、后血清的激光拉曼光谱。结果表明细胞培养液的拉曼光谱与空白对照有明显不同,且峰值与培养时间增成正相关;胃癌患者血清的拉曼光谱与健康人有显著差异;手术后胃癌患者血清的拉曼光谱峰值比术前明显降低。研究表明拉曼光谱可以作为胃癌细胞体外研究的检测手段,并有潜力成为胃癌筛查、预后监测及疗效判断的新方法。     

基于拉曼光谱的鼻咽癌细胞株总蛋白放射敏感性研究

本文以鼻咽癌细胞株CNE2为放射敏感性的研究对象,经不同剂量X射线照射及不同时间培养后分别提取总蛋白,用共聚焦显微拉曼光谱仪检测其拉曼光谱。统计分析表明:被测样品的拉曼光谱中观察到一些可以归属于蛋白质物质的较为明显的基团频率振动峰;不同剂量的X射线照射后,总蛋白质的平均拉曼光谱与对照组谱形基本一致,但与对照组间的光谱存在着对应峰信号强度的不同。实验提示:照射后谱峰强度的增大或减小,提示着相关物质含量有所改变。分析照射后癌细胞总蛋白拉曼光谱的变化情况,结合数学统计方法,以探寻放射敏感性的特征拉曼标志,可以作为研究肿瘤放射敏感性的手段之一。     

利用PCA-LDA和参数-CART方法对直肠癌血清拉曼光谱的分析

本文利用拉曼光谱技术检测由直肠癌的发生导致的血清成分的变化。比较了直肠癌患者和对照组之间血清拉曼光谱的差异,并对术后直肠癌患者血清拉曼光谱的变化也进行了比较,以监测术后治疗效果。结果表明在某些波数位置不同组的拉曼峰有统计学意义的变化,这些变化反应了血清中相应的生物物质的改变。之后,主成分分析(PCA)及峰强比参数这两种方法被用于原始拉曼光谱的特征变量的提取。将线性判别分析(LDA)和分类回归树(CART)两种判别分析法用于特征变量的判别分析。PCA-LDA和参数-CART方法的诊断准确率分别为87%和90%。     

基于SERS技术结合多变量统计分析胃癌患者血浆拉曼光谱

利用人体血浆的表面增强拉曼光谱（SERS）并结合多变量统计方法对胃癌的无损诊断分析进行了研究．检测了32例胃癌患者与33例正常健康人血浆SERS光谱,利用主成分分析（Pea）并结合线性判别分析（LDA）建立SERS光谱诊断多元统计算法模型．为验证所构建的PCA—LDA算法的有效性,将利用受试样品的工作特征（ROC）曲线方法对所构建的算法有效性进行评价．胃癌患者与正常健康入血浆SERS光谱之间的差别明显,且实验存在较好的重现性,利用PCA．LDA统计分析方法得到诊断特异性与灵敏度分别为91％与79．5％．通过SERS谱峰归属分析表明,癌症患者血浆与正常人血浆在生化成分上存在一定的差异．与正常健康人相比,胃癌患者血浆中的核酸、胶原、磷脂以及苯丙氨酸成分偏高,而氨基酸与糖类成分相对偏低．研究表明,血浆SERS光谱技术结合PCA．LDA统计分析能够很好地区分正常健康人与胃癌患者血浆．血浆表面增强拉曼光谱技术有望发展为一种无损探测与筛查胃癌的临床诊断工具．     

基于表面增强拉曼光谱的冠心病前瞻性诊断方法研究

前期研究表明血小板衍生生长因子-BB(platelet-derived growth factor-BB,PDGF-BB)与冠心病关系密切,本文基于表面增强拉曼光谱(surface-enhanced Raman spectroscopy,SERS)方法,结合PDGF-BB拉曼频移为1 509 cm~(-1)的拉曼特征峰,对60例冠心病患者,其中包括20例行皮冠状动脉介入治疗术(percutaneous coronary intervention,PCI)病人与40例未行PCI病人的尿液样本以及18例健康人尿液样本进行分析。结果显示:行PCI病人的尿液样本SERS光谱中可以检测到1 509 cm~(-1)的拉曼特征峰;而在健康人与大多数未行PCI病人的尿液SERS光谱中则检测不到。与临床资料对比发现,尿液SERS光谱与冠状动脉造影技术在判断心血管堵塞程度是否达到70%以上吻合度较高。基于表面增强拉曼光谱的冠心病检测方法有望发展为一种无创的冠心病前瞻性诊断工具,对于冠心病疑似病例是否需要行PCI提供可靠的临床诊断依据。     

家兔晶状体拉曼光谱空间分布研究

晶状体透明性的维持与其蛋白的结构成分极为密切,因此研究晶状体内的蛋白空间分布变化有重要意义.由实验中得到的450 cm~(-1)～2 000 cm~(-1)范围内健康家兔晶状体拉曼光谱,计算了家兔晶状体蛋白中三条氨基酸侧链和两条蛋白质主链拉曼谱峰沿赤道部和视轴部的光谱强度,根据实验结果讨论了这五条拉曼光谱在家兔晶状体中的空间分布特性.     

姜黄薄壁细胞原位拉曼光谱研究

用拉曼光谱原位分析姜黄橙黄色及黄色薄壁细胞中的物质。德宏、广西及西双版纳姜黄三种样品橙黄色细胞的拉曼光谱非常相似,较强峰出现在1 632/1 633/1 637、1 599/1 601/1 605、1 184/1 186/1 190 cm-1,中等强度的峰出现在1 529/1 528/1 534、1 425/1 426/1 430、1 306/1 308/1 311、1 235/1 235/1 239、1 167/1 168/1 173、1 122/1 125/1 130、967/969/975 cm-1。三种姜黄薄壁细胞中出现的强峰、次强峰位置、峰型都一致,说明三种姜黄橙色薄壁细胞中物质的主要成分相同。与姜黄素(curcumin)拉曼光谱的主要的19条谱线比较,在姜黄橙色细胞拉曼谱的17条谱峰中有16条与之对应。而黄色薄壁细胞中大部分谱线与支链淀粉的谱峰有较好的对应关系。用密度泛函理论计算了姜黄素的拉曼光谱,并对谱线进行了初步的归属。     

尿液表面增强拉曼光谱的初步研究

利用紫外与可见分光光度计测量银溶胶与尿液的吸收谱,采用拉曼光谱测量系统检测并研究分析了尿液加入银胶前后的拉曼光谱.基于表面增强技术,尿液的拉曼光谱信号得到显著增强,尿液中微弱的尿酸SERS信号被成功检测.文中对尿液的拉曼峰进行了谱峰归属,并分析了晨尿与夜尿的SERS谱.对晨尿的检测具有更高的可信度和信噪比.研究结果表明...     

动脉粥样硬化斑块的微区拉曼光谱检测

为探讨动脉粥样硬化斑块的微区拉曼光谱特征,以球囊损伤日本长耳白兔右侧颈总动脉后予以高脂饮食喂养,在实验过程中监测体重和血脂变化情况。3个月后,以中国斑点蝰蛇毒和组胺加以触发使斑块破裂,将动物处死并查找动脉硬化斑块,动脉组织经大体病理分类后,进行微区拉曼光谱及病理检测。结果显示:动脉粥样硬化斑块的拉曼光谱图在1450及1660cm-1处均有明显的胆固醇等脂质特征峰。特征峰曲线下相对面积统计结果表明:明显动脉粥样硬化斑块的谱峰下相对面积(5.80×10-3±3.51×10-3)显著高于轻度动脉粥样硬化组织(2.01×10-3±1.49×10-3)及正常动脉组织(1.01×10-3±0.94×10-3),P<0.05。正常动脉组织拉曼光谱曲线较光滑,无明显特征峰。血栓形成处拉曼光谱图荧光背底较强,未见特征谱峰。该研究结果证明微区拉曼光谱可以对动脉粥样硬化斑块的胆固醇等脂质含量进行特异性定量检测,表明微区拉曼光谱是评估动脉粥样硬化程度及斑块稳定性的可行方法。     

Study on gastric cancer blood plasma based on surface-enhanced Raman spectroscopy combined with multivariate analysis

A surface-enhanced Raman spectroscopy (SERS) method combined with multivariate analysis was developed for non-invasive gastric cancer detection. SERS measurements were performed on two groups of blood plasma samples: one group from 32 gastric patients and the other group from 33 healthy volunteers. Tentative assignments of the Raman bands in the measured SERS spectra suggest interesting cancer-specific biomolecular changes, including an increase in the relative amounts of nucleic acid, collagen, phospholipids and phenylalanine and a decrease in the percentage of amino acids and saccharide in the blood plasma of gastric cancer patients as compared with those of healthy subjects. Principal components analysis (PCA) and linear discriminant analysis (LDA) were employed to develop effective diagnostic algorithms for classification of SERS spectra between normal and cancer plasma with high sensitivity (79.5%) and specificity (91%). A receiver operating characteristic (ROC) curve was employed to assess the accuracy of diagnostic algorithms based on PCA-LDA. The results from this exploratory study demonstrate that SERS plasma analysis combined with PCA-LDA has tremendous potential for the non-invasive detection of gastric cancers.     

上皮性卵巢癌患者血清 microRNA-21 的水平及其临床意义研究

目的:检测上皮性卵巢癌患者血清中microRNA-21的表达,并探讨其作为标记物预测上皮性卵巢癌化疗耐药患者预后的可行性。方法:采用探针型实时荧光定量逆转录聚合酶链反应检测和比较20例上皮性卵巢癌患者和10例正常人卵巢血清标本中microRNA-21的表达,并分析血清microRNA-21水平与上皮性卵巢癌患者化疗耐药及其临床病理特征的相关性。结果:正常人、上皮性卵巢癌化疗敏感和化疗耐药患者血清中micro RNA-21的相对表达量分别为0.573±0.318、2.606±1.057、26.766±26.710,上皮性卵巢癌化疗敏感和化疗耐药患者血清中miR-21的相对表达量均显著高于正常人血清中miR-21的相对表达量(P<0.05),而上皮性卵巢癌化疗耐药患者血清中miR-21表达显著高于上皮性卵巢癌化疗敏感患者,差异有统计学意义(P<0.05)。上皮性卵巢癌化疗耐药患者血清miR-21表达水平与其手术-病理分期无及是否发生淋巴结转移均无明显相关性(P>0.05)。结论:上皮性卵巢癌患者血清microRNA-21水平显著升高,可能作为其化疗耐药的预测参考指标,但血清microRNA-21水平与上皮性卵巢癌化疗耐药患者的不良预后并无显著相关性。     

Label‐free diagnosis for colorectal cancer through coffee ring‐assisted surface‐enhanced Raman spectroscopy on blood serum

Surface‐enhanced Raman spectroscopy (SERS) is garnering considerable attention for the swift diagnosis of pathogens and abnormal biological status, that is, cancers. In this work, a simple, fast and inexpensive optical sensing platform is developed by the design of SERS sampling and data analysis. The pretreatment of spectral measurement employed gold nanoparticle colloid mixing with the serum from patients with colorectal cancer (CRC). The droplet of particle‐serum mixture formed coffee‐ring‐like region at the rim, providing strong and stable SERS profiles. The obtained spectra from cancer patients and healthy volunteers were analyzed by unsupervised principal component analysis (PCA) and supervised machine learning model, such as support‐vector machine (SVM), respectively. The results demonstrate that the SVM model provides the superior performance in the classification of CRC diagnosis compared with PCA. In addition, the values of carcinoembryonic antigen from the blood samples were compiled with the corresponding SERS spectra for SVM calculation, yielding improved prediction results.     

Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination

The NB12123 and CA125 radioimmunoassays, murine monoclonal antibody assays for measuring circulating levels of human ovarian tumor associated antigens NB/70K and CA 125, respectively, have been previously described. In the present study, preoperative serum samples were obtained from patients undergoing laparotomy for benign neoplastic ovarian tumors (N = 16), cancer of the cervix (N = 22), cancer of the uterus (N = 20), and cancer of the ovary (N = 47). Controls (N = 50) were obtained from healthy blood bank donors. No correlation was observed between the levels of NB/70K and CA 125 in these samples (r2 = .079, linear regression analysis). In general, increasing levels of both antigens were present with increasing tumor burden and higher histological grade. In addition, both markers were most elevated in the serum of ovarian cancer patients with serous and unclassified adenocarcinomas. Using 40 AU and 35 unit cut-offs for the NB/70K and CA 125 assay, respectively, overall specificity for healthy controls and patients with benign diseases approaches 100%. The combined sensitivity of the assays for ovarian cancer patient sera in this study indicates that the assays may be helpful in establishing a pre operative diagnosis of ovarian cancer. Complementarity of the NB/70K and CA 125 assays has been demonstrated, indicating that one or both assays may be used to monitor as many as 85% of ovarian cancer patients.     

Effects of blood collection conditions on ovarian cancer serum markers

Background

Evaluating diagnostic and early detection biomarkers requires comparing serum protein concentrations among biosamples ascertained from subjects with and without cancer. Efforts are generally made to standardize blood processing and storage conditions for cases and controls, but blood sample collection conditions cannot be completely controlled. For example, blood samples from cases are often obtained from persons aware of their diagnoses, and collected after fasting or in surgery, whereas blood samples from some controls may be obtained in different conditions, such as a clinic visit. By measuring the effects of differences in collection conditions on three different markers, we investigated the potential of these effects to bias validation studies.

Methodology and Principle Findings

We analyzed serum concentrations of three previously studied putative ovarian cancer serum biomarkers–CA 125, Prolactin and MIF–in healthy women, women with ovarian cancer undergoing gynecologic surgery, women undergoing surgery for benign ovary pathology, and women undergoing surgery with pathologically normal ovaries. For women undergoing surgery, a blood sample was collected either in the clinic 1 to 39 days prior to surgery, or on the day of surgery after anesthesia was administered but prior to the surgical procedure, or both. We found that one marker, prolactin, was dramatically affected by collection conditions, while CA 125 and MIF were unaffected. Prolactin levels were not different between case and control groups after accounting for the conditions of sample collection, suggesting that sample ascertainment could explain some or all of the previously reported results about its potential as a biomarker for ovarian cancer.

Conclusions

Biomarker validation studies should use standardized collection conditions, use multiple control groups, and/or collect samples from cases prior to influence of diagnosis whenever feasible to detect and correct for potential biases associated with sample collection.     

Investigation of ovarian cancer associated sialylation changes in N-linked glycopeptides by quantitative proteomics

ABSTRACT: BACKGROUND: In approximately 80% of patients, ovarian cancer is diagnosed when the patient is already in the advanced stages of the disease. CA125 is currently used as the marker for ovarian cancer; however, it lacks specificity and sensitivity for detecting early stage disease. There is a critical unmet need for sensitive and specific routine screening tests for early diagnosis that can reduce ovarian cancer lethality by reliably detecting the disease at its earliest and treatable stages. Results: In this study, we investigated the N-linked sialylated glycopeptides in serum samples from healthy and ovarian cancer patients using Lectin-directed Tandem Labeling (LTL) and iTRAQ quantitative proteomics methods. We identified 45 N-linked sialylated glycopeptides containing 46 glycosylation sites. Among those, ten sialylated glycopeptides were significantly up-regulated in ovarian cancer patients' serum samples. LC-MS/MS analysis of the non-glycosylated peptides from the same samples, western blot data using lectin enriched glycoproteins of various ovarian cancer type samples, and PNGase F (+/-) treatment confirmed the sialylation changes in the ovarian cancer samples. Conclusion: Herein, we demonstrated that several proteins are aberrantly sialylated in N-linked glycopeptides in ovarian cancer and detection of glycopeptides with abnormal sialylation changes may have the potential to serve as biomarkers for ovarian cancer.     

Detection of trophoblastic beta 1-glycoprotein in tumor tissue and blood in ovarian neoplasms

Using immunochemical analysis methods (the reaction of precipitation in agar, immunoenzymatic method, immunofluorescence), trophoblastic beta 1-glycoprotein (TBG) concentration in tumour tissue and in the blood serum of patients with ovarian cancer was studied. By rabbits immunization with glycoprotein fraction of ovarian adenocarcinoma, dissolved in 0.6 M sulfosalicylic acid, the authors obtained antibodies to TBG. Immunoenzymatic method showed, that TBG level is raised during ovarian cancer (more than 3 micrograms/l): in 18% of tumour extracts, in 12.5% of blood sera samples and in 41.6% of cases in ascites fluid. Utilizing indirect immunofluorescence method morphological structures of trophoblastic type were identified in paraffin sections of ovarian adenocarcinoma. The authors suppose, that such structures may be responsible for TBG biosynthesis in ovarian tumours.     

共振喇曼光谱技术在恶性肿瘤诊断中的应用

目的：探讨共振喇曼光谱技术用于早期恶性肿瘤诊断的研究。方法：利用氩离子激光作为线偏振光的特点,采集偏振荧光光谱,对荧光光谱的偏振态进行分析。利用不同荧光物质的荧光可能具有不同偏振态的特点减少其它荧光物质的荧光对光谱分析的影响。血清样品产生的荧光也具有确定的偏振性。对所检测病人血清经激光分析仪进行喇曼光谱技术分析,光谱数据经计算机软件处理,自动显示图谱和数据,并直接给出各项指标及诊断提示。本结果与细胞病理学结果进行了对照研究。结果：恶性肿瘤样本176例,检测出阳性病例141例,阳性符合率为80.1%;良性肿瘤样本52例,4例阳性,假阳性率为7.7%;正常体检样本248例,检测结果均为阴性。结论：喇曼光谱技术适用于肿瘤初筛、普查及早期诊断,有推广应用前途。     

Systematic evaluation of candidate blood markers for detecting ovarian cancer

Background

Epithelial ovarian cancer is a significant cause of mortality both in the United States and worldwide, due largely to the high proportion of cases that present at a late stage, when survival is extremely poor. Early detection of epithelial ovarian cancer, and of the serous subtype in particular, is a promising strategy for saving lives. The low prevalence of ovarian cancer makes the development of an adequately sensitive and specific test based on blood markers very challenging. We evaluated the performance of a set of candidate blood markers and combinations of these markers in detecting serous ovarian cancer.

Methods and Findings

We selected 14 candidate blood markers of serous ovarian cancer for which assays were available to measure their levels in serum or plasma, based on our analysis of global gene expression data and on literature searches. We evaluated the performance of these candidate markers individually and in combination by measuring them in overlapping sets of serum (or plasma) samples from women with clinically detectable ovarian cancer and women without ovarian cancer. Based on sensitivity at high specificity, we determined that 4 of the 14 candidate markers-MUC16, WFDC2, MSLN and MMP7-warrant further evaluation in precious serum specimens collected months to years prior to clinical diagnosis to assess their utility in early detection. We also reported differences in the performance of these candidate blood markers across histological types of epithelial ovarian cancer.

Conclusions

By systematically analyzing the performance of candidate blood markers of ovarian cancer in distinguishing women with clinically apparent ovarian cancer from women without ovarian cancer, we identified a set of serum markers with adequate performance to warrant testing for their ability to identify ovarian cancer months to years prior to clinical diagnosis. We argued for the importance of sensitivity at high specificity and of magnitude of difference in marker levels between cases and controls as performance metrics and demonstrated the importance of stratifying analyses by histological type of ovarian cancer. Also, we discussed the limitations of studies (like this one) that use samples obtained from symptomatic women to assess potential utility in detection of disease months to years prior to clinical detection.